PITX1 is a reliable biomarker for predicting prognosis in patients with oral epithelial dysplasia

Oncology Letters

Volumn 7, Issue 3, 2014, Pages 750-754

  Nakabayashi, Motoki ^a,b   Osaki, Mitsuhiko ^c   Kodani, Isamu ^a   Okada, Futoshi ^c   Ryoke, Kazuo ^a   Oshimura, Mitsuo ^a   Ito, Hisao ^a,c   Kugoh, Hiroyuki ^a  

^a TOTTORI UNIVERSITY   (Japan)

^b MATSUE RED CROSS HOSPITAL   (Japan)

^c TOTTORI UNIVERSITY   (Japan)

Author keywords

Biomarker; Immunohistochemistry; Oral epithelial dysplasia; PITX1

Indexed keywords

KI 67 ANTIGEN; TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR PITX1; UNCLASSIFIED DRUG;

ARTICLE; CANCER GROWTH; CANCER PROGNOSIS; CANCER STAGING; CELL TRANSFORMATION; CONTROLLED STUDY; DISEASE SEVERITY; DOWN REGULATION; EPITHELIUM DYSPLASIA; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MOUTH SQUAMOUS CELL CARCINOMA; PROTEIN EXPRESSION;

EID: 84893024960     PISSN: 17921074     EISSN: 17921082     Source Type: Journal    
DOI: 10.3892/ol.2013.1775     Document Type: Article

References (37)

1. Bánóczy J and Csiba A: Occurrence of epithelial dysplasia in oral leukoplakia. Analysis and follow-up study of 12 cases. Oral Surg Oral Med Oral Pathol 42: 766-774, 1976.
2. van der Waal I: Potentially malignant disorders of the oral and oropharyngeal mucosa; terminology, classification and present concepts of management. Oral Oncol 45: 317-323, 2009.
3. Gupta PC, Mehta FS, Daftary DK, et al: Incidence rates of oral cancer and natural history of oral precancerous lesions in a 10-year follow-up study of Indian villagers. Community Dent Oral Epidemiol 8: 283-333, 1980.
4. Silverman S Jr, Gorsky M and Lozada F: Oral leukoplakia and malignant transformation. A follow-up study of 257 patients. Cancer 53: 563-568, 1984.
5. Bouquot JE and Whitaker SB: Oral leukoplakia-rationale for diagnosis and prognosis of its clinical subtypes or 'phases'. Quintessence Int 25: 133-140, 1994.
6. Napier SS and Speight PM: Natural history of potentially malignant oral lesions and conditions: an overview of the literature. J Oral Pathol Med 37: 1-10, 2008.
7. Piemonte ED, Lazos JP and Brunotto M: Relationship between chronic trauma of the oral mucosa, oral potentially malignant disorders and oral cancer. J Oral Pathol Med 39: 513-517, 2010.
8. Reibel J: Prognosis of oral pre-malignant lesions: significance of clinical, histopathological, and molecular biological characteristics. Crit Rev Oral Biol Med 14: 47-62, 2003.
9. Imoto I, Pimkhaokham A, Watanabe T, et al: Amplification and overexpression of TGIF2, a novel homeobox gene of the TALE superclass, in ovarian cancer cell lines. Biochem Biophys Res Commun 276: 264-270, 2000.
10. Lamonerie T, Tremblay JJ, Lanctôt C, et al: Ptx1, a bicoid-related homeo box transcription factor involved in transcription of the pro-opiomelanocortin gene. Genes Dev 10: 1284-1295, 1996.
11. DeLaurier A, Schweitzer R and Logan M: Pitx1 determines the morphology of muscle, tendon, and bones of the hindlimb. Dev Biol 299: 22-34, 2006.
12. Shang J, Li X, Ring HZ, et al: Backfoot, a novel homeobox gene, maps to human chromosome 5 (BFT) and mouse chromosome 13 (Bft). Genomics 40: 108-113, 1997.
13. Lanctôt C, Moreau A, Chamberland M, et al: Hindlimb patterning and mandible development require the Ptx1 gene. Development126: 1805-1810, 1999.
14. Shang J, Luo Y and Clayton DA: Backfoot is a novel homeobox gene expressed in the mesenchyme of developing hindlimb. Dev Dyn 209: 242-253, 1997.
15. Libório TN, Acquafreda T, Matizonkas-Antonio LF, et al: In situ hybridization detection of homeobox genes reveals distinct expression patterns in oral squamous cell carcinomas. Histopathology 58: 225-233, 2011.
16. Lord RV, Brabender J, Wickramasinghe K, et al: Increased CDX2 and decreased PITX1 homeobox gene expression in Barrett's esophagus and Barrett's-associated adenocarcinoma. Surgery 138: 924-931, 2005.
17. Chen YN, Chen H, Xu Y, et al: Expression of pituitary homeobox 1 gene in human gastric carcinogenesis and its clinicopathological significance. World J Gastroenterol 14: 292-297, 2008.
18. Qi DL, Ohhira T, Fujisaki C, et al: Identification of PITX1 as a TERT suppressor gene located on human chromosome 5. Mol Cell Biol 31: 1624-1636, 2011.
19. Chen Y, Knösel T, Ye F, et al: Decreased PITX1 homeobox gene expression in human lung cancer. Lung Cancer 55: 287-294, 2007.
20. Stender JD, Stossi F, Funk CC, et al: The estrogen-regulated transcription factor PITX1 coordinates gene-specific regulation by estrogen receptor-alpha in breast cancer cells. Mol Endocrinol25: 1699-1709, 2011.
21. Calvisi DF, Ladu S, Conner EA, et al: Inactivation of Ras GTPase-activating proteins promotes unrestrained activity of wild-type Ras in human liver cancer. J Hepatol 54: 311-319, 2011.
22. Knösel T, Chen Y, Hotovy S, et al: Loss of desmocollin 1-3 and homeobox genes PITX1 and CDX2 are associated with tumor progression and survival in colorectal carcinoma. Int J Colorectal Dis 27: 1391-1399, 2012.
23. Hamidov Z, Altendorf-Hofmann A, Chen Y, et al: Reduced expression of desmocollin 2 is an independent prognostic biomarker for shorter patients survival in pancreatic ductal adenocarcinoma. J Clin Pathol 64: 990-994, 2011.
24. Kwok SC, Liu X, Mangel P and Daskal I: PTX1(ERGIC2)-VP22 fusion protein upregulates interferon-beta in prostate cancer cell line PC-3. DNA Cell Biol 25: 523-529, 2006.
25. Osaki M, Chinen H, Yoshida Y, et al: Decreased PITX1 gene expression in human cutaneous malignant melanoma and its clinicopathological significance. Eur J Dermatol Jun 28, 2013 (Epub ahead of print).
26. Pindborg JJ, Smith CJ, van der Waal I: Histological typing of cancer and precancer of the oral mucosa (2nd edition), World Health Organization. Springer-Verlag, Berlin, pp 24-40, 1997.
27. Kodani I, Shomori K, Osaki M, et al: Expression of minichromosome maintenance 2 (MCM2), Ki-67, and cell-cycle-related molecules, and apoptosis in the normal-dysplasia-carcinoma sequence of the oral mucosa. Pathobiology 69: 150-158, 2001.
28. Gouvêa AF, Vargas PA, Coletta RD, et al: Clinicopathological features and immunohistochemical expression of p53, Ki-67, Mcm-2 and Mcm-5 in proliferative verrucous leukoplakia. J Oral Pathol Med 39: 447-452, 2010.
29. Nasser W, Flechtenmacher C, Holzinger D, et al: Aberrant expression of p53, p16INK4a and Ki-67 as basic biomarker for malignant progression of oral leukoplakias. J Oral Pathol Med40: 629-635, 2011.
30. Nogami T, Kuyama K and Yamamoto H: Histopathological and immunohistochemical study of malignant transformation of oral leukoplakia, with special reference to apoptosis-related gene products and proliferative activity. Acta Otolaryngol123: 767-775, 2003.
31. Matsubara R, Kuwano S, Kiyosue T, et al: Increased ΔNp63 expression is predictive of malignant transformation in oral epithelial dysplasia and poor prognosis in oral squamous cell carcinoma. Int J Oncol 39: 1391-1399, 2011.
32. Thomson PJ, Soames JV, Booth C and O'Shea JA: Epithelial cell proliferative activity and oral cancer progression. Cell Prolif35 (Suppl 1): S110-S120, 2002.
33. Kumar P, Kane S and Rathod GP: Coexpression of p53 and Ki 67 and lack of c-erbB2 expression in oral leukoplakias in India. Braz Oral Res 26: 228-234, 2012.
34. Iamaroon A, Khemaleelakul U, Pongsiriwet S and Pintong J: Co-expression of p53 and Ki67 and lack of EBV expression in oral squamous cell carcinoma. J Oral Pathol Med 33: 30-36, 2004.
35. Gerdes J, Lemke H, Baisch H, et al: Cell cycle analysis of a cell proliferation-associated human nuclear antigen defined by the monoclonal antibody Ki-67. J Immunol 133: 1710-1715, 1984.
36. Oliveira LR and Ribeiro-Silva A: Prognostic significance of immunohistochemical biomarkers in oral squamous cell carcinoma. Int J Oral Maxillofac Surg 40: 298-307 2011.
37. Kolfschoten IG, van Leeuwen B, Berns K, et al: A genetic screen identifies PITX1 as a suppressor of RAS activity and tumorigenicity. Cell 121: 849-858 2005.